Management Of Endometriosis Related Pain: Is Dienogest A Good Choice?

Endometriosis is the chronic disease, which primarily occurs, in female of reproductive agewherein endometriotic tissue is found in the area other than endometrial layer of uterus. It mainlycause painful symptoms, fatigue leading to decrease in the quality of life causing to substantialeconomic burden to the patient, their family and society. As per present, there is no permanentcure for endometriosis, so management really focuses on relieving the painful symptoms andreducing the endometriotic lesions and finally improving the quality of the life of the women.Surgical management has also not proved to be of that beneficial effect as the recurrence aftersurgery is common. Dienogest (DNG) is the hybrid progesterone, which has recently been usedin clinical trials and studies for its effects on treatment of endometriosis. Two major clinical trialshave been performed in Europe and Japan, including dose-ranging, placebo-controlled, activecomparator-controlled and long term up to65weeks. These studies have shown that use of2mg/day of DNG is effective in reducing the endometriotic related pelvic pain, reducing theendometriotic lesion and also improves the quality of life. DNG in these studies have shown the favorable safety and tolerability with minimal adverse effect and high rates of compliance andlow withdrawal rates. This review article describes these clinical trial evidences whichcharacterizes the safety and efficacy of DNG on endometriosis and its relevance in the treatmentof endometriosis in the clinical practice.